(302 days)
Silver Antimicrobial Gauze Sponge/Bandage devices are indicated for external use only. These devices are intended for use in the management of Pressure ulcers, Stasis ulcers, Diabetic foot ulcers, First and second degree burns, Lacerations, Abrasions, Skin tears, Surgical incision sites, Graft sites, and Donor sites.
The new product is a non-X-ray detectable, non-absorbable gauze sponge/bandage consisting of cotton, rayon/polyester formed material that has been treated with proprietary silver saccharinate which can give rise to ionic silver when put into contact with aqueous moisture such as that in wound fluid. Sterile gauze sponges and bandages of various sizes and formats in individual single use packaging are for use as primary or secondary wound dressings.
The provided text describes a 510(k) submission for a medical device and its clearance by the FDA. However, it does not contain specific acceptance criteria, performance metrics, or study details that would allow for the completion of the requested table and information.
The document primarily focuses on:
- Device Description: What the Silver Antimicrobial Wound Gauze is made of and how it works.
- Intended Use: The types of wounds it's designed to treat.
- Technological Characteristics: The mechanism of action (ionic silver antimicrobial activity).
- Pre-Clinical Testing: In vitro antimicrobial activity against various strains and duration of activity (up to 5 days), along with biocompatibility assurance (ISO standard).
- Regulatory Information: Comparison to legally marketed predicate devices, substantial equivalence determination, and FDA clearance.
Missing Information:
The document explicitly states: "No performance standards are prescribed for the new product." This means that detailed acceptance criteria and a study proving the device meets those criteria, as typically seen in a rigorous clinical trial, are not present in this 510(k) summary. The submission relies on establishing substantial equivalence to predicate devices and demonstrating in vitro antimicrobial activity and biocompatibility rather than presenting a comparative clinical performance study with acceptance criteria.
Therefore, I cannot fill out the requested table or provide the detailed study information because it is not present in the provided text.
{0}------------------------------------------------
JUN 9 - 2005
510(k) Summary
| Sponsor: | Medline IndustriesOne Medline PlaceMundelein, Il 60060 |
|---|---|
| Contact Person: | Dr. Bruce L. Gibbins: (503)-624-9830 |
| Device Name | Silver Antimicrobial Wound Gauze for external use |
| Common Name: | Gauze Sponge/Bandage |
| Classification and Panel: | Unclassified; General and Plastic Surgery |
Legally marketed device(s) for substantial equivalence comparison:
SilvaSorb Silver Antimicrobial Wound Dressing (AcryMed, Inc., OR) Kerlix AMD (Kendall, MD) Bulkee Gauze/Avant Gauze Sponge (Medline, IL) Aquacel Ag (Convatec, NJ)
Description of Device: The new product is a non-X-ray detectable, non-absorbable gauze sponge/bandage consisting of cotton, rayon/polyester formed material that has been treated with proprietary silver saccharinate which can give rise to ionic silver when put into contact with aqueous moisture such as that in wound fluid. Sterile gauze sponges and bandages of various sizes and formats in individual single use packaging are for use as primary or secondary wound dressings. Sterility assurance will conform to AAMI/ANSI/ISO 11137-1994.
Intended Use of the Device: Silver Antimicrobial Gauze Sponge/Bandage devices are indicated for external use only. These devices are intended for use in the management of Pressure ulcers, Stasis ulcers, Diabetic foot ulcers, First and second degree burns, Lacerations, Abrasions, Skin tears, Surgical incision sites, Graft sites, and Donor sites.
Technological Characteristics: The Silver Antimicrobial Wound Gauze is an antimicrobial barrier wound covering that gives rise to ionic silver when in contact with aqueous moisture. lonic silver possesses antimicrobial activity when in a moist environment such as when contaminated by bodily fluids including wound exudate.
Pre-Clinical Testing: The new product has been shown to possess antimicrobial activity against 29 strains of bacteria, fungi and yeasts in vitro including E. coli (2 strains), Klebsiella pneumoniae (3 strains), Candida albicans (3 strains), Candida parapsilosis, Staphylococcus aureus, Methiacillin Resistant Staphylococcus aureus (2 strains), coagulate negative Staphylococcus aureus, Pseudomonas aeruginosa (3 strains), Bacillus subtilis, Enterobacter cloacae (2 strains), Enterococcus faecalis (2 strains), Vancomycin Resistant Enterobacter faecium (2 strains), Aspergillus niger, Serratia marcescens, Candida galbrata, Citrobacter diversus, Citrobacter kasseri, and Staphylococcus saprophyticus. Silver antimicrobial wound gauze has been shown by in vitro serial transfer testing to be active for up to 5 days. Safety and biocompatibility assurance has been established in accordance with Part-1 of the ISO standard (Biological Evaluation of Medical Devices).
{1}------------------------------------------------
Manufacturing: Silver Antimicrobial Wound Gauze will be manufactured according to the product specifications and under good manufacturing practices that ensure the device is safe and effective for its intended use.
Performance Standards: No performance standards are prescribed for the new product.
{2}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/2/Picture/1 description: The image is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of an eagle with three curved lines representing its wings. The eagle is facing to the right.
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
JUN 9 - 2005
Medline Industries Incorporated C/o Bruce Gibbins, Ph.D. Chief Technical Officer AcryMed Incorporated 12232 SW Garden Place Portland, Oregon 97223
Re: K042164
Trade/Device Name: Silver Antimicrobial Gauze Regulatory Class: Unclassified Product Code: FRO Dated: May 23, 2005 Received: May 24, 2005
Dear Dr. Gibbins:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
{3}------------------------------------------------
Page 2 - Bruce Gibbins, Ph.D.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115 . Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Signature
Miriam C. Provost, Ph.D. Acting Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
Indications for Use
K042164 510(k) Number (if known): Silver Antimicrobial Gauze Device Name: Pressure ulcers Indications For Use: Stasis ulcers Diabetic foot ulcers First and second degree burns Lacerations Abrasions Skin tears Surgical incision sites Graft site Donor sites
Prescription Use _____________________________________________________________________________________________________________________________________________________________ × (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
(Levision Sign-Off) Division of General, Restorative and Neurological Devices
Number K042164
Page 1 of
N/A